An Exploratory Phase II Study to Demonstrate the Safety and Efficacy of A4250 in Children With Cholestatic Pruritus
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Albireo
- 入组人数
- 24
- 试验地点
- 7
- 主要终点
- AE evaluation
研究概览
简要总结
This study will evaluate A4250 (IBATinhibitor) as a treatment option in pediatric patients with chronic cholestasis with main emphasis on safety evaluation and on effects on pruritus
详细描述
The primary aims of this Phase II exploratory study in patients treated with A4250 due to cholestasis induced pruritus are to:
- Assess the safety and tolerability of A4250, orally administered first as a single dose and then during a four week treatment period, as determined by the occurrence of treatment-emergent SAEs
- Explore changes in serum total bile acids after a four week treatment period
Secondary safety aims include assessment of the safety and tolerability of A4250, orally administered first as a single dose and then during a four week treatment period, as determined by the occurrence of treatment-emergent AEs and changes in safety parameters including laboratory tests and vital signs
Secondary efficacy aims are to:
- Demonstrate the efficacy of A4250, orally administered during a four week treatment period, on liver biochemistry variables and on pruritus parameters
- Evaluate the pharmacokinetic properties of A4250 orally administered first as a single dose and then after a four week treatment period
- Evaluate changes in VAS-itching score after a four week treatment period
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 1 Year 至 18 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of pruritus due to chronic cholestasis based on history and investigator judgment. This will include but will not be restricted to patients with Progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome (ALGS), Biliary Atresia and Sclerosing Cholangitis
排除标准
- •Any condition that in the opinion of the investigator constitutes a risk for the patient or a contraindication for participation and completion of the study, or could interfere with study objectives, conduct, or evaluations
- •Clinical or biochemical signs of decompensated liver disease
- •Liver transplantation
研究组 & 干预措施
A4250 6
Dose 6
干预措施: A4250 (Drug)
A4250 1
Dose I
干预措施: A4250 (Drug)
A4250 2
Dose 2
干预措施: A4250 (Drug)
A4250 3
Dose 3
干预措施: A4250 (Drug)
A4250 4
Dose 4
干预措施: A4250 (Drug)
A4250 5
Dose 5
干预措施: A4250 (Drug)
结局指标
主要结局
AE evaluation
时间窗: 4 wks
Treatment-emergent SAEs Adverse events
次要结局
- Bile acid changes(4 weeks)